PATENT CLAIM ANALYSIS

Application Number: 16097322
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["540", "593000"]

Abstract:
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

Claim (Index 20):
The method of  claim 18 , wherein said cancer is selected from the group consisting of: acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome, Hodgkin's disease, and non-Hodgkin's lymphoma.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 97.0
- Lexical Diversity: 1.32432
- Patent Class: 540.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15242638', '14787866', '14651711', '14794911', '13961044']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7373721546248575
- 35 USC 102 Novelty (BERT): 0.5722623141063318
- Combined Prediction Score: 0.720861170573005
- Mean Citation Score: 374.493262
- Max Citation Score: 460.23492000000016
- Similarity Product: 362.1353143551565

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test